TrialBMC medicine2024

Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial.

Wenjuan Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.